18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Recent advances in the formulation of PLGA microparticles for controlled drug delivery

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Polymeric microparticles (MPs) are recognized as very popular carriers to increase the bioavailability and bio-distribution of both lipophilic and hydrophilic drugs. Among different kinds of polymers, poly-(lactic- co-glycolic acid) (PLGA) is one of the most accepted materials for this purpose, because of its biodegradability (due to the presence of ester linkages that are degraded by hydrolysis in aqueous environments) and safety (PLGA is a Food and Drug Administration (FDA)-approved compound). Moreover, its biodegradability depends on the number of glycolide units present in the structure, indeed, lower glycol content results in an increased degradation time and conversely a higher monomer unit number results in a decreased time. Due to this feature, it is possible to design and fabricate MPs with a programmable and time-controlled drug release. Many approaches and procedures can be used to prepare MPs. The chosen fabrication methodology influences size, stability, entrapment efficiency, and MPs release kinetics. For example, lipophilic drugs as chemotherapeutic agents (doxorubicin), anti-inflammatory non-steroidal (indomethacin), and nutraceuticals (curcumin) were successfully encapsulated in MPs prepared by single emulsion technique, while water-soluble compounds, such as aptamer, peptides and proteins, involved the use of double emulsion systems to provide a hydrophilic compartment and prevent molecular degradation. The purpose of this review is to provide an overview about the preparation and characterization of drug-loaded PLGA MPs obtained by single, double emulsion and microfluidic techniques, and their current applications in the pharmaceutical industry.

          Graphic abstract

          Related collections

          Most cited references158

          • Record: found
          • Abstract: found
          • Article: not found

          Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

          In past two decades poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications. PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mechanical properties and most importantly, is a FDA approved polymer. In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small molecule drugs, proteins and other macromolecules in commercial use and in research. This manuscript describes the various fabrication techniques for these devices and the factors affecting their degradation and drug release.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum

              The skin offers an accessible and convenient site for the administration of medications. To this end, the field of transdermal drug delivery, aimed at developing safe and efficacious means of delivering medications across the skin, has in the past and continues to garner much time and investment with the continuous advancement of new and innovative approaches. This review details the progress and current status of the transdermal drug delivery field and describes numerous pharmaceutical developments which have been employed to overcome limitations associated with skin delivery systems. Advantages and disadvantages of the various approaches are detailed, commercially marketed products are highlighted and particular attention is paid to the emerging field of microneedle technologies.
                Bookmark

                Author and article information

                Contributors
                concetta.dinatale@iit.it
                raffaele.vecchione@iit.it
                Journal
                Prog Biomater
                Prog Biomater
                Progress in Biomaterials
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                2194-0509
                2194-0517
                15 October 2020
                15 October 2020
                December 2020
                : 9
                : 153-174
                Affiliations
                [1 ]GRID grid.25786.3e, ISNI 0000 0004 1764 2907, Center for Advanced Biomaterials for HealthCare@CRIB, , Istituto Italiano di Tecnologia, ; Largo Barsanti e Matteucci 53, 80125 Naples, Italy
                [2 ]GRID grid.4691.a, ISNI 0000 0001 0790 385X, Department of Pharmacy, CIRPEB: Centro Interuniversitario di Ricerca sui Peptidi Bioattivi, , University of Naples “Federico II”, ; Via Mezzocannone 16, 80134 Naples, Italy
                [3 ]GRID grid.4691.a, ISNI 0000 0001 0790 385X, Interdisciplinary Research Center of Biomaterials, CRIB, , University Federico II, ; P.leTecchio 80, 80125 Naples, Italy
                [4 ]GRID grid.4691.a, ISNI 0000 0001 0790 385X, Department of Chemical, Materials and Industrial Production Engineering (DICMaPI), , University of Naples Federico II, ; P.le Tecchio 80, 80125 Naples, Italy
                Author information
                http://orcid.org/0000-0002-2874-6539
                Article
                139
                10.1007/s40204-020-00139-y
                7718366
                33058072
                55d7bed1-6ceb-4e00-9022-517ec7d88642
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 13 July 2020
                : 28 September 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100007076, Fondazione Italiana per la Ricerca sul Cancro;
                Funded by: IBSA FOUNDATION
                Funded by: Istituto Italiano di Tecnologia
                Categories
                Review Paper
                Custom metadata
                © Islamic Azad University 2020

                plga mps,double emulsion,single emulsion,drug encapsulation,drug release

                Comments

                Comment on this article